Back to top
more

Century Therapeutics (IPSC)

(Real Time Quote from BATS)

$0.54 USD

0.54
242,720

0.00 (-0.44%)

Updated Aug 7, 2025 12:40 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value D Growth B Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 34% (84 out of 246)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

All You Need to Know About Century Therapeutics (IPSC) Rating Upgrade to Strong Buy

by Zacks Equity Research

Century Therapeutics (IPSC) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

Zacks Equity Research

Despite Fast-paced Momentum, Century Therapeutics (IPSC) Is Still a Bargain Stock

by Zacks Equity Research

Century Therapeutics (IPSC) could be a great choice for investors looking to buy stocks that have gained strong momentum recently but are still trading at reasonable prices. It is one of the several stocks that made it through our 'Fast-Paced Momentum at a Bargain' screen.

Zacks Equity Research

Century Therapeutics (IPSC) Is Attractively Priced Despite Fast-paced Momentum

by Zacks Equity Research

Century Therapeutics (IPSC) made it through our 'Fast-Paced Momentum at a Bargain' screen and could be a great choice for investors looking for stocks that have gained strong momentum recently but are still trading at reasonable prices.

Zacks Equity Research

Fast-paced Momentum Stock Century Therapeutics (IPSC) Is Still Trading at a Bargain

by Zacks Equity Research

Century Therapeutics (IPSC) could be a great choice for investors looking to buy stocks that have gained strong momentum recently but are still trading at reasonable prices. It is one of the several stocks that made it through our 'Fast-Paced Momentum at a Bargain' screen.

Zacks Equity Research

Century Therapeutics, Inc. (IPSC) Q1 Earnings and Revenues Top Estimates

by Zacks Equity Research

Century Therapeutics (IPSC) delivered earnings and revenue surprises of 387.10% and 139.84%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Journey Medical Corporation (DERM) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Journey Medical (DERM) delivered earnings and revenue surprises of 25% and 10.55%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Verrica Pharmaceuticals Inc. (VRCA) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Verrica Pharmaceuticals (VRCA) delivered earnings and revenue surprises of 28.57% and 22.82%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Century Therapeutics, Inc. (IPSC) May Report Negative Earnings: Know the Trend Ahead of Q1 Release

by Zacks Equity Research

Century Therapeutics (IPSC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Madrigal (MDGL) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Madrigal (MDGL) delivered earnings and revenue surprises of 8.29% and 20.35%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Century Therapeutics (IPSC) Upgraded to Buy: What Does It Mean for the Stock?

by Zacks Equity Research

Century Therapeutics (IPSC) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Zacks Equity Research

Century Therapeutics, Inc. (IPSC) Reports Q4 Loss, Misses Revenue Estimates

by Zacks Equity Research

Century Therapeutics (IPSC) delivered earnings and revenue surprises of 4.44% and 89.06%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Verrica Pharmaceuticals Inc. (VRCA) Reports Q4 Loss, Lags Revenue Estimates

by Zacks Equity Research

Verrica Pharmaceuticals (VRCA) delivered earnings and revenue surprises of 4% and 80.78%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

What Makes Century Therapeutics (IPSC) a New Buy Stock

by Zacks Equity Research

Century Therapeutics (IPSC) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Zacks Equity Research

Century Therapeutics, Inc. (IPSC) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

Century Therapeutics (IPSC) delivered earnings and revenue surprises of 19.57% and 69.74%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

electroCore (ECOR) Stock Jumps 11.7%: Will It Continue to Soar?

by Zacks Equity Research

electroCore (ECOR) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Zacks Equity Research

Century Therapeutics, Inc. (IPSC) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Century Therapeutics (IPSC) delivered earnings and revenue surprises of 24% and 40.18%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Century Therapeutics (IPSC) Moves to Buy: Rationale Behind the Upgrade

by Zacks Equity Research

Century Therapeutics (IPSC) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Zacks Equity Research

Century Therapeutics, Inc. (IPSC) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Century Therapeutics (IPSC) delivered earnings and revenue surprises of 10% and 185%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Amneal (AMRX) Stock Jumps 7.3%: Will It Continue to Soar?

by Zacks Equity Research

Amneal (AMRX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Zacks Equity Research

How Much Upside is Left in Century Therapeutics, Inc. (IPSC)? Wall Street Analysts Think 193.4%

by Zacks Equity Research

The average of price targets set by Wall Street analysts indicates a potential upside of 193.4% in Century Therapeutics, Inc. (IPSC). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Zacks Equity Research

Organogenesis (ORGO) Reports Break-Even Earnings for Q4

by Zacks Equity Research

Organogenesis (ORGO) delivered earnings and revenue surprises of 100% and 6.45%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Catalyst Pharmaceutical (CPRX) Tops Q4 Earnings and Revenue Estimates

by Zacks Equity Research

Catalyst (CPRX) delivered earnings and revenue surprises of 10.42% and 4.53%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Century (IPSC) Up 36% on FDA Nod to Begin Phase I Lupus Study

by Zacks Equity Research

Century (IPSC) set to begin early-stage study on lead product candidate, CNTY-101, for treatment of systemic lupus erythematosus following IND clearance by FDA. The stock rises 36%.

Zacks Equity Research

Century Therapeutics, Inc. (IPSC) Reports Q2 Loss, Misses Revenue Estimates

by Zacks Equity Research

Century Therapeutics, Inc. (IPSC) delivered earnings and revenue surprises of -3.70% and 93.58%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Revolution Medicines, Inc. (RVMD) Reports Q2 Loss, Misses Revenue Estimates

by Zacks Equity Research

Revolution Medicines, Inc. (RVMD) delivered earnings and revenue surprises of -10.84% and 4.40%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?